

The aging oocyte—can mitochondrial function be improved?

Yaakov Bentov, M.D., and Robert F. Casper, M.D.

Toronto Centre for Advanced Reproductive Technology, Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Toronto, and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada

In recent years, social and cultural trends have resulted in women delaying childbirth, thereby leading to reproductive senescence as a growing public health problem. We discuss potential etiologies for age-related female reproductive decline. We bring supportive evidence to the central role of mitochondrial dysfunction and oxygen radicals in the process of aging in general and reproductive senescence specifically. We also explore the role of coenzyme Q10 deficiency as a contributing factor and the effects of its administration. (Fertil Steril® 2013;99:18–22. ©2013 by American Society for Reproductive Medicine.)

Key Words: Reproductive senescence, reactive oxygen species, mitochondrial dysfunction, mitochondrial nutrients, coenzyme Q10

Discuss: You can discuss this article with its authors and with other ASRM members at <http://fertilityforum.com/caspeerrf-aging-oocyte-mitochondria-coenzyme-q10/>



Use your smartphone to scan this QR code and connect to the discussion forum for this article now.*

* Download a free QR code scanner by searching for "QR scanner" in your smartphone's app store or app marketplace.

Female fertility peaks around age 25 and after age 35 suffers a rapid decline. For most women, the beginning of the fifth decade of life marks the end of their reproductive life. This decline is primarily due to an age-related decrease in oocyte quality rather than changes in endometrial receptivity, as indicated by the continuous high rate of success of donor oocytes in in vitro fertilization (IVF) treatments for recipients of advanced age (1). Cultural and social trends have resulted in an increased number of women delaying childbirth, thereby increasing the burden of reproductive senescence on public health.

The main reasons for the poor reproductive performance of older patients are reduced ovarian reserve and an increased rate of chromosomal aberrations, which leads to an increased risk of miscarriages and aneuploidy (2, 3). The estimated incidence of trisomy 21 at age 25 is 1 in 1,500, at age 40 is 1 in

60, and at age 49 is 1 in 11 (3). However, chromosome 21 is only one out of 23 pairs of chromosomes. Sher et al. (4) performed oocyte and embryo numeric karyotyping using comparative genomic hybridization (CGH). This method enables determination of the number of copies of all the chromosomes. Their findings suggested that the incidence of oocyte aneuploidy for women at a mean age of 27.0 ± 2.5 years was 65% and would presumably be even higher in older women. In that study, euploid embryos were far more likely to survive and develop to the blastocyst stage by day 5 than were aneuploid embryos (93% vs. 21%). In addition, oocytes with a proper chromosomal number almost always retained correct ploidy after fertilization, as 87% of the euploid oocytes developed into euploid embryos. Their findings show that embryo ploidy is linearly propagated after fertilization, which underscores

the immense importance of oocyte euploidy in early embryo survival. These reproductive changes associated with aging are also accompanied by decreased ovarian reserve (5), thought to be due to follicle atresia as a result of programmed cell death.

There are two leading theories regarding the age-related decline in oocyte quality. The first is that selection of the highest-quality oocytes during early reproductive years leaves the less favorable oocytes for more advanced age. The other is that the process of aging itself may exert an unfavorable influence on the oocytes that remain dormant in the ovary before being selected in the ovulatory cohort.

The process of aging and its effects on somatic cells as well as oocytes is still largely unknown. However, recent data suggest a central role for mitochondria. One of the hallmarks of aging is accumulation of point mutations and deletions of mitochondrial DNA (mtDNA) (6). These mutations are unevenly distributed, can accumulate clonally, and can cause a mosaic pattern of respiratory chain deficiencies in tissues characterized by energy consumption. The cause of these mutations has been strongly debated.

Received October 4, 2012; revised and accepted November 19, 2012.

Y.B. has nothing to disclose. R.F.C. has received a grant from CIHR, and consulting fees and travel support from Ferring.

Reprint requests: Robert F. Casper, M.D., 150 Bloor Street West, Suite 210, Toronto, Ontario M5S 2X9, Canada (E-mail: casper@lunenfeld.ca).

Fertility and Sterility® Vol. 99, No. 1, January 2013 0015-0282/\$36.00

Copyright ©2013 American Society for Reproductive Medicine, Published by Elsevier Inc. <http://dx.doi.org/10.1016/j.fertnstert.2012.11.031>

A very elegant study by Trifunovic et al. (7) examined this question by creating homozygous knock-in mice that express a proofreading-deficient version of PolgA, the catalytic subunit of mtDNA polymerase. The result was a threefold to fivefold increase in the level of point mutations and deletions of mtDNA. This increase in somatic mtDNA mutations was associated with reduced life span and premature onset of aging-related phenotypes such as weight loss, reduced subcutaneous fat, alopecia, kyphosis, osteoporosis, and anemia. Most interestingly, the mtDNA-mutator mice suffered a profound reduction in fertility. The females could not conceive after the age of 20 weeks despite being exposed to males for several months.

Wang et al. (8) studied the adverse effects of maternal diabetes on embryo development and pregnancy in a diabetic mouse model. It is well known that mothers with diabetes, which is characterized by high oxidative stress (9) resulting in mitochondrial dysfunction (10), experience poor reproductive outcomes similar to older patients, with an increased risk of miscarriages, birth defects, and fetal aneuploidies. This poor reproductive performance was found to be associated with mitochondrial dysfunction similar to that found in the embryos of older mothers, including an alteration in mitochondrial ultrastructure and increased mtDNA copy number accompanied by markedly reduced levels of adenosine 5'-triphosphate (ATP) and tricarboxylic acid (TCA) cycle metabolites. Furthermore, oocytes from diabetic mice displayed a higher frequency of spindle defects and chromosome misalignment in meiosis, resulting in increased aneuploidy rates in ovulated oocytes. The investigators concluded that the toxic conditions to which oocytes are exposed in diabetic mothers induce significant mitochondrial damage. Because mitochondria are solely inherited from the mother, the embryo inherits a dysfunctional energy-producing mechanism for the support of the crucial stages of its development.

Cytoplasmic transfer between oocytes was initially developed to treat infertility patients who exhibited persistent poor embryonic development and recurrent implantation failure after IVF. The technique was based on the assumption that the ooplasm of eggs, particularly from older women, was defective and could be rescued by the introduction of ooplasm from eggs of younger donors. The procedure involved microinjection of 5% to 15% of the ooplasm from a young, presumably fertile donor oocyte into a putative defective recipient oocyte (11). This treatment was based on results of earlier animal experiments involving mouse embryos from strains that experience a developmental block. Injection of cytoplasm from an oocyte of a nonblocking into a blocking strain increased cleavage rates of the recipient embryos compared with noninjected controls, suggesting the presence of an ooplasmic factor capable of rescuing the developmental block (12). Transfer of ooplasm from healthy fertile donors into oocytes of patients with repeated embryonic developmental failure has been used clinically, resulting in the birth of several children worldwide (11–14). Despite the fact that many different cytoplasmic components are injected, it is commonly believed that the beneficial effects are derived from the mitochondria. Children born as a result of this technique have demonstrated heteroplasmy (15), the

presence of two different strains of mitochondrial DNA in their genome; as a result, there is now a moratorium on ooplasm transfer in the United States and Canada.

These examples, in which the process of reproductive senescence was induced at an early age by insults to mitochondrial function and corrected by the transfer of healthy mitochondria to an affected oocyte, suggest that reproductive aging is not the result of a preferential selection of oocytes but rather the effect of the aging process and, more specifically, the aging effect on the function of the mitochondria.

Oogenesis and the formation of the ovarian follicles start in fetal life. Both the oocyte and the primordial follicle may reside within the ovary for as long as 50 years before growth and development into mature oocytes. Immature oocytes in the ovarian cortex are diploid, containing 46 chromosomes arrested in prophase of the first meiotic division. After follicle growth and maturation, the onset of the luteinizing hormone surge or the human chorionic gonadotropin trigger during assisted reproduction treatment leads to resumption of meiosis in the oocyte. During this process, the chromosomes condense, align in pairs, and then separate via pulling apart of the chromosomes by the spindle fibers, resulting in a mature oocyte that contains 23 chromosomes. The other set of chromosomes is isolated outside the oolemma in the first polar body. The second meiotic division commences with the penetration of a viable sperm. The oocyte then extrudes 23 sister chromatids, resulting in a second polar body and a fertilized zygote that has a normal diploid complement of 46 chromosomes. The process of pulling chromosomes outside the egg to form the first and second polar bodies requires a significant amount of energy, which is provided by ATP from oxidative phosphorylation in the mitochondria.

The oocyte has, by far, the largest number of mitochondria and mtDNA copies of any cell (approximately 2×10^5 copies) (16), at least one or two orders of magnitude more than somatic cells like muscle and neurons that have high energy requirements. Primordial germ cells contain only a few copies of a founder mitochondrial genome (~200 mtDNA copies) enclosed in immature mitochondria that replicate and eventually populate the new organism. It was originally thought that this process (mitochondrial bottleneck theory) resulted in selection of mitochondria with the best mtDNA while eliminating possibly mutated mtDNA, and resulting in a more homogenous mtDNA population in primordial germ cells. However, a recent study (17) showed that selection of mitochondria and mtDNA in the oocyte is a random process that does not screen for the intact wild-type mitochondrial genome. Therefore, mitochondria with abnormal mtDNA are just as likely to be inherited by the offspring as normal mitochondria. During the process of mitochondrial replication and expansion, oocytes will dramatically amplify their population of mitochondria, thereby supplying each gamete with a large copy number of both normal and abnormal mtDNA.

Mitochondrial replication is controlled by several nuclear encoded transcription factors that stabilize (TFAM) and unwind (Peo1/SSbp1) mtDNA. Mitochondrial DNA integrity is maintained by mtDNA polymerase (Polga/b) (18). These factors are mainly involved with modulation of mtDNA copy number rather than mitochondrial function. There are

additional factors that coordinate the metabolic demands of the cell with mitochondrial biogenesis. These involve nuclear-encoded transcription factors such as PPAR γ coactivator-1 α/β (PGC-1), Nrf-1/2, as well as sensors such as AMP-activated kinase (AMPK) that respond to cellular caloric status, obesity, and diabetes (19). The total number of mtDNA copies in the developing embryo does not change from fertilization until the blastocyst stage, despite numerous cell divisions, resulting in a progressively diluted mtDNA content in each of the blastomeres (20).

An association between low mtDNA copy number and ability of the oocyte to become fertilized has been described (21). In addition, oocytes of women with ovarian insufficiency have been reported to contain a lower mtDNA copy number than women with a normal ovarian profile (22).


Oocytes mostly rely on energy (e.g., ATP) produced by mitochondria via oxidative phosphorylation (OXPHOS), a process that relies on the oxidation of nutrients to phosphorylated adenosine diphosphate (ADP) (23). As seen in Figure 1, OXPHOS involves the action of the mitochondrial respiratory chain consisting of five complexes located on the inner mitochondrial membrane. The reduced form of nicotinamide-adenine dinucleotide (NADH) generated by the Krebs cycle is initially oxidized at complex I. As the electrons from NADH are passed to the first mobile electron acceptor, oxidized coenzyme Q10 (CoQ10), the energy is converted by the ejection of protons to the intermembrane space. CoQ10 can also accept electrons from complex II donated by the reduced form of flavin-adenine dinucleotide (FADH₂), another product of the Krebs cycle, thereby bypassing complex I and one proton ejection site. CoQ10 then donates electrons to cytochrome *b* in complex III. In complex III, electrons are passed to cytochrome *c*₁ with the dissipative ejection of protons. Cytochrome *c*₁ transfers its electrons to the second mobile element in the cytochrome chain, cytochrome *c*. Cytochrome *c* in turn reduces cytochrome *a*,*a*₃ in complex

4, which ultimately reduces molecular oxygen to form water. This final dissipation of the redox energy in NADH/FADH at complex IV is also associated with a final ejection of protons. The ejection of protons into the intermembrane space creates a chemical and electrical gradient that eventually drives the phosphorylation of ADP to ATP through complex V (24).

One of the byproducts of mitochondrial respiration is the production of reactive oxygen species (ROS). About 90% of cellular ROS is produced by the mitochondria. In the past, it was thought that the generation of ROS was “leakage” or an unproductive side reaction. More recently, it has been suggested that mitochondrial ROS may actually be very important in various redox-dependant signaling processes (25–27) and in the aging clock. The two major sites for ROS generation are complexes I and III (see Fig. 1). In these sites, large changes in potential energy of the electrons relative to reduction of oxygen occur. Complex III includes the Q cycle in which CoQ10 regulates the transfer of electrons to cytochrome *b* and may contribute to the generation of O₂⁻ (28). CoQ10 is a lipophilic molecule that is synthesized within the mitochondria and is essential for antioxidant defence. There is a gradual, age-related decline in the tissue levels of CoQ10 (29), and certain drugs such as statins block its synthesis (30). Mutations of genes involved in coQ10 synthesis may lead to CoQ10 deficiency, characterized by clinical disorders involving mitochondrial dysfunction in the nervous system, skeletal muscles, and endocrine glands (31).

Experimental use of inhibitors of complexes I and III may result in a large increase in ROS formation. Increased ROS production has been correlated with fatty acid oxidation, high oxygen tension, apoptosis, enzyme deficiencies that reduce the activity of OXPHOS, and reduced action of antioxidants (24). High levels of ROS are associated with mtDNA damage; mtDNA is particularly vulnerable due to its proximity to the source of oxidants, lack of a protective histone covering, and lack of noncoding introns that increase the

FIGURE 1



The electron transport chain that supports the process of oxidative phosphorylation (OXPHOS) in the mitochondria. This illustration shows the five complexes and the flow of electrons and protons as well as the central role of oxidized coenzyme Q10 (CoQ10) as an electron and proton transporter; describes the sites of reactive oxygen species (ROS) production and the Q cycle; and identifies the central role of CoQ10 in the flow of electrons and protons, showing how the associated increase ROS in a deficiency in CoQ10 leads to a compensatory increase in the number of sites producing ROS. Also shown is the proximity of ROS production sites to the energy-producing proteins and mitochondrial DNA.

Bentov. Aging oocyte and mitochondrial function. *Fertil Steril* 2013.

likelihood of damage to a coding region. This observed increased sensitivity of the mtDNA to oxidative damage has led to the concept of a vicious cycle in which an initial ROS-induced impairment of mitochondria leads to increased oxidant production, which in turn leads to further mitochondrial damage. Old mitochondria appear morphologically and functionally altered and produce more oxidants and less ATP (32).

One of the features of human aging is a decline in tissue CoQ10 concentration (29). Quinzii et al. (33) examined the effects of different levels of CoQ10 deficiency on ROS production, mitochondrial function, and cell viability. They showed that a severe deficiency (<20% of normal) causes a marked bioenergetics defect without significant antioxidant stress. Intermediate CoQ10 deficiency (30% to 45% of normal), which is more typical of age-related CoQ10 deficiency, caused moderate bioenergetic defects but a marked increase in ROS production, lipid oxidation, and cell death. CoQ10 supplementation was shown to normalize the bioenergetic status and oxidative balance in the fibroblasts of CoQ10-deficient patients in vitro (34). Our findings in the late-maternal-age oocyte mouse model have been similar (35, 36). We observed a significant decline in the expression of the enzymes involved in CoQ10 production in cumulus cells with aging, consistent with our hypothesis that decreased energy production in oocytes with aging may be related to deficiency of CoQ10. In this aged animal model, we showed that 52-week-old mice treated with CoQ10 had a significant increase in the number of ovulated eggs after stimulation, a lower mitochondrial membrane potential and mitochondrial copy numbers, and restored citrate/ATP ratio in comparison with the aged controls (35, 36). The CoQ10-treated group also had a significantly larger litter size, a definitive positive outcome.

Can the aging process in reproductive function be altered? We believe the observations presented in this review point to the conclusion that a mechanism to increase mitochondrial function and energy production should have a positive impact on pregnancy outcome in older women. In this regard, supplementing the diets of older women with mitochondrial nutrients may potentially be beneficial. Mitochondrial nutrients are naturally occurring chemicals that have been used successfully to treat conditions associated with diminished mitochondrial energy production, and they appear to be very safe for both mother and fetus. Supplementation with mitochondrial nutrients such as CoQ10 and α -lipoic acid (ALA) may be able to reduce the risk of trisomy and other types of chromosomal aneuploidies related to oocyte aging via increasing energy for chromosomal disjunction. Studies on bovine oocytes suggest that CoQ10 could be added to culture media of the embryos for significantly improved mitochondrial function and ATP production (37). A strategy of supplementation of mitochondrial nutrients may lead to improvement in oocyte and embryo quality, and subsequently, a healthy pregnancy outcome for older women. We believe that large, properly randomized, properly controlled trials are now needed to test the effect of mitochondrial nutrients on clinical reproductive outcomes.

REFERENCES

1. Wright VC, Chang J, Jeng G, Macaluso M. Assisted reproductive technology surveillance—United States, 2005. *MMWR Surveill Summ* 2008;57:1–23.
2. Bartmann AK, Romao GS, Ramos Eda S, Ferriani RA. Why do older women have poor implantation rates? A possible role of the mitochondria. *J Assist Reprod Genet* 2004;21:79–83.
3. Hook EB. Rates of chromosome abnormalities at different maternal ages. *Obstet Gynecol* 1981;58:282–5.
4. Sher G, Keskinetepe L, Keskinetepe M, Ginsburg M, Maassarani G, Yakut T, et al. Oocyte karyotyping by comparative genomic hybridization [correction of hybridization] provides a highly reliable method for selecting “competent” embryos, markedly improving in vitro fertilization outcome: a multi-phase study. *Fertil Steril* 2007;87:1033–40.
5. Freeman SB, Yang Q, Allran K, Taft LF, Sherman SL. Women with a reduced ovarian complement may have an increased risk for a child with Down syndrome. *Am J Hum Genet* 2000;66:1680–3.
6. Mulder DW. Clinical limits of amyotrophic lateral sclerosis. *Adv Neurol* 1982;36:15–22.
7. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature* 2004;429:417–23.
8. Wang Q, Ratchford AM, Chi MM, Schoeller E, Frolova A, Schedl T, Moley KH. Maternal diabetes causes mitochondrial dysfunction and meiotic defects in murine oocytes. *Mol Endocrinol* 2009;23:1603–12.
9. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. *J Biochem Mol Toxicol* 2003;17:24–38.
10. Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. *J Neurol Sci* 2005;233:145–62.
11. Cohen J, Scott R, Alikani M, Schimmel T, Munne S, Levron J, et al. Ooplasmic transfer in mature human oocytes. *Mol Hum Reprod* 1998;4:269–80.
12. Muggleton-Harris A, Whittingham DG, Wilson L. Cytoplasmic control of pre-implantation development in vitro in the mouse. *Nature* 1982;299:460–2.
13. Barritt J, Willadsen S, Brenner C, Cohen J. Cytoplasmic transfer in assisted reproduction. *Hum Reprod Update* 2001;7:428–35.
14. Barritt JA, Brenner CA, Malter HE, Cohen J. Mitochondria in human offspring derived from ooplasmic transplantation. *Hum Reprod* 2001;16:513–6.
15. Harvey AJ, Gibson TC, Quebedeaux TM, Brenner CA. Impact of assisted reproductive technologies: a mitochondrial perspective of cytoplasmic transplantation. *Curr Top Dev Biol* 2007;77:229–49.
16. May-Panloup P, Chretien MF, Malthiery Y, Reynier P. Mitochondrial DNA in the oocyte and the developing embryo. *Curr Top Dev Biol* 2007;77:51–83.
17. Inoue K, Nakada K, Ogura A, Isobe K, Goto Y, Nonaka I, Hayashi JI. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. *Nat Genet* 2000;26:176–81.
18. Tynismaa H, Suomalainen A. Mouse models of mtDNA replication diseases. *Methods* 2010;51:405–10.
19. Seo AY, Joseph AM, Dutta D, Hwang JC, Aris JP, Leeuwenburgh C. New insights into the role of mitochondria in aging: mitochondrial dynamics and more. *J Cell Sci* 2010;123:2533–42.
20. Thundathil J, Filion F, Smith LC. Molecular control of mitochondrial function in preimplantation mouse embryos. *Mol Reprod Dev* 2005;71:405–13.
21. Reynier P, May-Panloup P, Chretien MF, Morgan CJ, Jean M, Savagner F, et al. Mitochondrial DNA content affects the fertilizability of human oocytes. *Mol Hum Reprod* 2001;7:425–9.
22. May-Panloup P, Chretien MF, Jacques C, Vasseur C, Malthiery Y, Reynier P. Low oocyte mitochondrial DNA content in ovarian insufficiency. *Hum Reprod* 2005;20:593–7.
23. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Cellular energetics: glycolysis, aerobic oxidation, and photosynthesis. In: *Molecular cell biology*. 4th ed. New York: W.H. Freeman; 2000. Chap. 16.
24. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. *Cell* 2005;120:483–95.
25. Dada LA, Chandel NS, Ridge KM, Pedemonte C, Bertorello AM, Sznajder JJ. Hypoxia-induced endocytosis of Na, K-ATPase in alveolar epithelial cells is

- mediated by mitochondrial reactive oxygen species and PKC-zeta. *J Clin Invest* 2003;111:1057–64.
26. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. *Science* 2002;295:2450–2.
 27. Werner E, Werb Z. Integrins engage mitochondrial function for signal transduction by a mechanism dependent on Rho GTPases. *J Cell Biol* 2002;158:357–68.
 28. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. *J Biol Chem* 2002;277:44784–90.
 29. Pignatti C, Cocchi M, Weiss H. Coenzyme Q10 levels in rat heart of different age. *Biochem Exp Biol* 1980;16:39–42.
 30. Mas E, Mori TA. Coenzyme Q(10) and statin myalgia: what is the evidence? *Curr Atheroscler Rep* 2010;12:407–13.
 31. Quinzii CM, Hirano M, DiMauro S. CoQ10 deficiency diseases in adults. *Mitochondrion* 2007;7(Suppl):S122–6.
 32. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. *Proc Natl Acad Sci USA* 1994;91:10771–8.
 33. Quinzii CM, Tadesse S, Naini A, Hirano M. Effects of inhibiting CoQ10 biosynthesis with 4-nitrobenzoate in human fibroblasts. *PLoS ONE* 2012;7:e30606.
 34. Lopez LC, Quinzii CM, Area E, Naini A, Rahman S, Schuelke M, et al. Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. *PLoS ONE* 2010;5:e11897.
 35. Burstein E, Bentov Y, Omari S, Yavorska T, Jurisicova A, Casper RF. Mitochondria in the offspring of old mice exhibit alterations similar to those seen in their mothers [abstract]. *Fertil Steril* 2010;94(Suppl):S57.
 36. Burstein E, Perumalsamy A, Bentov Y, Esfandiari N, Jurisicova A, Casper RF. Co-enzyme q10 supplementation improves ovarian response and mitochondrial function in aged mice [abstract]. *Fertil Steril* 2009;92(Suppl):S31.
 37. Gendelman M, Roth Z. Incorporation of coenzyme Q10 into bovine oocytes improves mitochondrial features and alleviates the effects of summer thermal stress on developmental competence. *Biol Reprod* 2012;87:118.